Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

Mathieu Grangeon; Pascale Tomasini; Solene Chaleat; Arnaud Jeanson; Maxime Souquet-Bressand; Nataliya Khobta; Julien Bermudez; Youssef Trigui; Laurent Greillier; Marilyne Blanchon; Mohamed Boucekine; Celine Mascaux; Fabrice Barlesi

doi:10.1016/j.cllc.2018.10.002

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

Mathieu Grangeon, Pascale Tomasini, Solene Chaleat, Arnaud Jeanson, Maxime Souquet-Bressand, Nataliya Khobta, Julien Bermudez, Youssef Trigui, Laurent Greillier, Marilyne Blanchon, Mohamed Boucekine, Celine Mascaux, Fabrice Barlesi

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

155 Citations (Scopus)

Résumé

Immune checkpoints inhibitors (ICIs)in advanced non–small-cell lung cancer are associated with immune-related adverse events (IRAEs). We retrospectively analyzed the efficacy of ICIs in a cohort of 270 patients with the objective to assess the association of IRAEs with ICI efficacy. We found a statistically significant efficacy difference in favor of patients with IRAEs. These results could be used to determine ICI responders.

langue originale	Anglais
Pages (de - à)	201-207
Nombre de pages	7
journal	Clinical Lung Cancer
Volume	20
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.cllc.2018.10.002
état	Publié - 1 mai 2019
Modification externe	Oui

Accès au document

10.1016/j.cllc.2018.10.002

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Grangeon, M., Tomasini, P., Chaleat, S., Jeanson, A., Souquet-Bressand, M., Khobta, N., Bermudez, J., Trigui, Y., Greillier, L., Blanchon, M., Boucekine, M., Mascaux, C., & Barlesi, F. (2019). Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer. Clinical Lung Cancer, 20(3), 201-207. https://doi.org/10.1016/j.cllc.2018.10.002

@article{5bba467b91cc4e679e59fc357dcb5a62,

title = "Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer",

abstract = "Immune checkpoints inhibitors (ICIs)in advanced non–small-cell lung cancer are associated with immune-related adverse events (IRAEs). We retrospectively analyzed the efficacy of ICIs in a cohort of 270 patients with the objective to assess the association of IRAEs with ICI efficacy. We found a statistically significant efficacy difference in favor of patients with IRAEs. These results could be used to determine ICI responders.",

keywords = "Immuno-related adverse events, Non-small cell lung cancer, Response, Survival",

author = "Mathieu Grangeon and Pascale Tomasini and Solene Chaleat and Arnaud Jeanson and Maxime Souquet-Bressand and Nataliya Khobta and Julien Bermudez and Youssef Trigui and Laurent Greillier and Marilyne Blanchon and Mohamed Boucekine and Celine Mascaux and Fabrice Barlesi",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = may,

day = "1",

doi = "10.1016/j.cllc.2018.10.002",

language = "English",

volume = "20",

pages = "201--207",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "3",

}

Grangeon, M, Tomasini, P, Chaleat, S, Jeanson, A, Souquet-Bressand, M, Khobta, N, Bermudez, J, Trigui, Y, Greillier, L, Blanchon, M, Boucekine, M, Mascaux, C & Barlesi, F 2019, 'Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer', Clinical Lung Cancer, VOL. 20, Numéro 3, p. 201-207. https://doi.org/10.1016/j.cllc.2018.10.002

TY - JOUR

T1 - Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

AU - Grangeon, Mathieu

AU - Tomasini, Pascale

AU - Chaleat, Solene

AU - Jeanson, Arnaud

AU - Souquet-Bressand, Maxime

AU - Khobta, Nataliya

AU - Bermudez, Julien

AU - Trigui, Youssef

AU - Greillier, Laurent

AU - Blanchon, Marilyne

AU - Boucekine, Mohamed

AU - Mascaux, Celine

AU - Barlesi, Fabrice

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Immune checkpoints inhibitors (ICIs)in advanced non–small-cell lung cancer are associated with immune-related adverse events (IRAEs). We retrospectively analyzed the efficacy of ICIs in a cohort of 270 patients with the objective to assess the association of IRAEs with ICI efficacy. We found a statistically significant efficacy difference in favor of patients with IRAEs. These results could be used to determine ICI responders.

AB - Immune checkpoints inhibitors (ICIs)in advanced non–small-cell lung cancer are associated with immune-related adverse events (IRAEs). We retrospectively analyzed the efficacy of ICIs in a cohort of 270 patients with the objective to assess the association of IRAEs with ICI efficacy. We found a statistically significant efficacy difference in favor of patients with IRAEs. These results could be used to determine ICI responders.

KW - Immuno-related adverse events

KW - Non-small cell lung cancer

KW - Response

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85056270711&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.10.002

DO - 10.1016/j.cllc.2018.10.002

M3 - Article

C2 - 30442524

AN - SCOPUS:85056270711

SN - 1525-7304

VL - 20

SP - 201

EP - 207

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -